Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHow the two doses compare, and what the evidence says about the difference
Picture where you are: six months in, sitting on 1.7mg
You have been titrating for roughly five months. The first pen (0.25mg) felt cautious. Then 0.5mg, 1.0mg, and now 1.7mg. Your appetite has shifted; you are probably eating less without forcing it. But your prescriber mentioned a final step. The standard licensed schedule for Wegovy injection runs 0.25mg, 0.5mg, 1.0mg, 1.7mg and then 2.4mg, each held for approximately four weeks, with 2.4mg as the maintenance dose. For most people, 1.7mg is a staging post, not a destination.
The titration is designed the way it is for a reason: each dose increase risks more gastrointestinal side effects, and moving gradually gives your system time to adapt. At 1.7mg you are one rung below the dose that featured in the pivotal trial data. Whether your body needs that final step (and whether it is the right time) is exactly the kind of question a prescriber weighs at your repeat review. You can read more about how the full Wegovy dose schedule works if you want the broader picture before your next consultation.
What the trial data shows about 2.4mg specifically
The STEP 1 trial (published in the New England Journal of Medicine) ran at the 2.4mg maintenance dose for 68 weeks. Participants with obesity and without type 2 diabetes lost around 15% of body weight on average, compared to about 2.4% with placebo, alongside lifestyle support. That 15% figure belongs to 2.4mg; no equivalent randomised data exists for 1.7mg held long-term as the maintenance dose, because the licence and the trials were built around 2.4mg as the endpoint.
The table below summarises the key factual differences between the two doses.
| Feature | Wegovy 1.7mg | Wegovy 2.4mg |
|---|---|---|
| Role in schedule | Penultimate titration step (~4 weeks) | Licensed maintenance dose |
| Trial weight-loss data | Not the primary trial dose; used as a step | ~15% average body-weight reduction at 68 weeks (STEP 1, NEJM) |
| Licensed UK maintenance dose? | No | Yes |
| Higher-dose option above this | Yes (2.4mg is next | Yes) 7.2mg pen approved by MHRA, 14 April 2026 |
| GI side-effect risk vs previous step | Higher than 1.0mg; settles with time | May be higher than 1.7mg; typically transient |
It is also worth knowing that the MHRA approved a dedicated single-dose 7.2mg Wegovy pen on 14 April 2026, a further step above 2.4mg for adults with a BMI of 30 or above, titrated by the prescriber. That context matters: 2.4mg is not the ceiling of what semaglutide can do, even though it is the standard maintenance target. More detail on what to expect at the 2.4mg dose is on its own page.
Side effects: does moving from 1.7mg to 2.4mg make them worse?
The honest answer is: possibly, briefly. The most common effects with Wegovy are gastrointestinal, nausea, loose stools, constipation, indigestion, and occasionally vomiting. They tend to peak in the first week or two after a dose increase and then ease. If 1.7mg caused you noticeable nausea, there is a fair chance the first week or two at 2.4mg will feel similar before settling. If 1.7mg was comfortable, the step up is usually manageable.
The NHS medicines page for semaglutide lists the full side-effect profile, which your prescriber will have considered. The key signals that need prompt attention regardless of dose are severe, persistent abdominal pain that radiates to the back (which can indicate pancreatitis), signs of a serious allergic reaction, and symptoms of gallbladder problems. Report any suspected side effects through the MHRA Yellow Card scheme. A practical note: keeping your 1.7mg pen at the same spot in the fridge door each week (alongside anything else you refrigerate daily) makes it easier to remember your injection and notice if a pen is missing or accidentally left out.
For a closer look at what people typically experience at this specific step, the weight-loss outcomes at 1.7mg vs 2.4mg page goes into more detail on the results side.
Which dose is right for you: how a prescriber actually decides
A prescriber considers three things when you reach this point: how much weight you have lost so far, how well you tolerated 1.7mg, and whether there is any clinical reason to hold rather than advance. Someone who lost 12% at 1.7mg and had minimal side effects is in a different position from someone who lost 4% and is still nauseated, and both might get a different recommendation again from someone with a relevant comorbidity.
Staying at 1.7mg indefinitely is not the standard clinical approach; the medicine is dosed and licensed on the expectation that most people will reach 2.4mg. That said, a prescriber may choose to hold at 1.7mg for a further period if tolerability warrants it, and you can find more guidance on moving from 1.7mg to 2.4mg Wegovy if you want to go into that decision in more depth. What does not happen at a well-run online pharmacy is the dose changing without a clinical review of your progress. At nume, every repeat order is reviewed by a GPhC-registered prescriber before anything is dispatched, there is no automatic rollover. If you want to understand how our clinical team approaches these decisions, our clinical lead's profile explains the oversight model. And if you are still working out whether to start or which product suits you, check your eligibility through a free consultation, which is where the prescriber conversation properly begins.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.